Mucoadhesives containing antifungal complexed with beta-cyclodextrin for Denture Stomatitis treatment

Abstract

Denture Stomatitis (DS) is the most prevalent oral candidiasis among removable dentures users. Although conventional treatment with topical or systemic antifungals is effective in improving its signs and symptoms, it has been commonly observed case of reinfection of the oral mucosa within two weeks after treatment. In recent decades, mucoadhesives with a drug delivery system have become a trend in pharmaceutical technology, as they enable faster absorption directly in the infected site, in addition to better adhesion in mucous tissues and drug bioavailability. Furthermore, inclusion complexes with cyclodextrins have been suggested to increase drug solubility and molecule stability. Therefore, the aim of this study will be to develop and characterize mucoadhesives containing nystatin (Nys) or chlorhexidine (Chx) pure or complexed with beta-cyclodextrin (beta-CD) for the treatment of DS. Initially, the Minimum Inhibitory Concentrations (MICs) to the growth of Candida albicans from mucoadhesive formulations containing pure (Nys and Chx) or complexed antifungals (Nys:beta-CD and Chx:beta-CD) will be determined by broth microdilution (EUCAST). The Minimum Fungicidal Concentration (MFC) will also be determined by counting UFC/mL. Subsequently, the mucoadhesive formulations will be evaluated according to their rheological properties in an oscillatory rheometer, bioadhesive in a texturometer and cytotoxic using the MTT, Live-Dead and Alamar Blue tests in 3D cell culture. Data will be obtained and submitted to appropriate statistical tests (±=0.05). (AU)